SVRA News and Press, Savara Inc. From 06/26/23

Target Enrollment was 160 Patients, IMPALA-2 Enrolled 164 Patients Company Remains On-Track to Report Top Line Data by End of 2Q 2024 Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that enrol...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fires...

2023-05-16 12:32:00 ET Shares of Savara (NASDAQ: SVRA) rose more than 9% Tuesday morning after the company released first-quarter earnings. The stock is up more than 38% so far this year. Savara is a a clinical-stage pharmaceutical company that specializes in therapies to treat ...

2023-05-16 10:07:34 ET Gainers: Phio Pharmaceuticals ( PHIO ) +30% . Coya Therapeutics ( COYA ) +23% . Nanobiotix ( NBTX ) +12% . Savara ( SVRA ) +12% . Bellerophon Therapeutics ( BLPH ) +11% . Losers: Eloxx Pharmaceutical...

2023-05-16 09:25:00 ET Savara ( NASDAQ: SVRA ), a biotech focused on respiratory disorders, added ~7% pre-market Tuesday after Jefferies upgraded its shares to Buy from Hold citing over 100% upside in the event of a positive Phase 3 readout from its lead program molgramostim. ...

Pivotal Phase 3 IMPALA-2 Trial Remains On-Track Company expects trial to be fully enrolled in June 2023, on-track to report top line data by end of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for ...

2023-03-31 00:32:20 ET Savara press release ( NASDAQ: SVRA ): Q4 GAAP EPS of -$0.07. As of December 31, 2022, the Company had cash, cash equivalents and short-term investments of $125.9 million. For further details see: Savara GAAP EPS of -$0.07

Pivotal Phase 3 IMPALA-2 Trial Remains On-Track with Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease ...

2023-03-10 11:41:50 ET Gainers: Euda Health ( EUDA ) +53% . Unicycive ( UNCY ) +27% . Tenon Medical ( TNON ) +12% . Rain ( RAIN ) +11% . Altamira ( CYTO ) +11% . Losers: Meihua International ( MHUA ) -34% . Fr...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET. A live webcast of the presentation will be avai...